On Friday, Celldex Therapeutics Inc (NASDAQ: CLDX) opened lower -3.09% from the last session, before settling in for the closing price of $21.33. Price fluctuations for CLDX have ranged from $18.61 to $49.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 43.00% over the last five years. Company’s average yearly earnings per share was noted -34.42% at the time writing. With a float of $64.70 million, this company’s outstanding shares have now reached $66.37 million.
The firm has a total of 186 workers. Let’s measure their productivity. In terms of profitability, gross margin is 77.61%, operating margin of -2778.89%, and the pretax margin is -2248.76%.
Celldex Therapeutics Inc (CLDX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Celldex Therapeutics Inc is 2.54%, while institutional ownership is 109.67%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.18% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Check out the current performance indicators for Celldex Therapeutics Inc (CLDX). In the past quarter, the stock posted a quick ratio of 18.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 195.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.93 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Analysing the last 5-days average volume posted by the [Celldex Therapeutics Inc, CLDX], we can find that recorded value of 0.75 million was lower than the volume posted last year of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 58.79%. Additionally, its Average True Range was 1.26.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 15.79%, which indicates a significant decrease from 43.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.07% in the past 14 days, which was lower than the 50.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.44, while its 200-day Moving Average is $30.96. Now, the first resistance to watch is $21.45. This is followed by the second major resistance level at $22.24. The third major resistance level sits at $22.67. If the price goes on to break the first support level at $20.23, it is likely to go to the next support level at $19.80. Should the price break the second support level, the third support level stands at $19.01.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
There are currently 66,384K shares outstanding in the company with a market cap of 1.37 billion. Presently, the company’s annual sales total 7,020 K according to its annual income of -157,860 K. Last quarter, the company’s sales amounted to 1,180 K and its income totaled -47,090 K.
